Europe approves Revolution Medicines' RAS-blocking pancreatic cancer pill
The European Commission approved RASONQUE (daraxonrasib) from Revolution Medicines for metastatic pancreatic adenocarcinoma — the first broad RAS-targeted drug cleared in Europe. The once-daily pill beat chemotherapy in a 500-patient Phase 3 trial, with median overall survival of 12.4 months versus 6.7.
- Original source: healthandme.com.
- The source published it on Nov 16, 2026 at 8:14 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The European Commission has cleared RASONQUE, or daraxonrasib, for adults with metastatic pancreatic adenocarcinoma — making it the first broad RAS-targeted medicine approved in Europe for the disease. The daily oral pill from Revolution Medicines is an option for patients whose cancer has progressed despite earlier treatment, and it can be used whether or not a RAS tumor mutation has been identified.
The approval covers every EU member state plus Iceland, Norway and Liechtenstein. It stops at those borders: the UK and Switzerland run their own regulatory reviews. The decision came through an expedited assessment under the EMA's Cancer Medicines Pathfinder project, which fast-tracks promising medicines aimed at serious unmet needs.
Regulators leaned on the Phase 3 RASolute 302 trial, which pitted daraxonrasib against standard chemotherapy in 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. About 92% of participants had confirmed RAS G12 mutations. Per the European Medicines Agency, median overall survival hit 12.4 months on daraxonrasib versus 6.7 months on chemo, while median progression-free survival came in at 7.2 months against 3.6 months.
Daraxonrasib works differently from drugs that chase a single RAS mutation. It binds cyclophilin A to form a complex that latches onto active RAS proteins and blocks the growth signals driving cancer cells to multiply, inhibiting multiple RAS variants at once. The FDA approved the drug in August 2026, citing survival gains in both RAS G12 mutation carriers and the overall trial population.
Common side effects include diarrhea, skin rash, stomatitis, nausea and vomiting. The label also carries warnings for severe skin and soft tissue reactions, gastrointestinal perforation and interstitial lung disease or pneumonitis. Revolution Medicines said it is working with health systems and stakeholders across Europe to open access, though patients will have to wait on each country's pricing, health technology assessment and reimbursement process.
The stakes are steep. Roughly 147,000 people are diagnosed with pancreatic cancer in Europe every year, and the five-year survival rate sits below 10%. Because early-stage disease shows few or no symptoms, about 80% of patients learn they have it only after the cancer has already spread.
TopicsRevolution Medicines · daraxonrasib · RASONQUE · European Commission · European Medicines Agency · FDA · RASolute 302 · cyclophilin A
Source: healthandme.com
Written by AI from verified reporting.
More stories
- Health & science wdsu.com 0 viewsFDA Greenlights First Treatment for Deadly Sanfilippo Syndrome
- Health & science finance.yahoo.com 0 viewsNovartis' Cosentyx wins FDA nod as first anti-IL-17 biologic for PMR
- Health & science casrai.org 0 viewsFDA greenlights giredestrant-everolimus duo for ESR1-mutated breast cancer
- Health & science nbcnews.com Caught by @nina.anggraini29 0 viewsMeasles Is Endemic Again as the U.S. Loses Its Elimination Status

